Literature DB >> 29984806

Normalization of data for viability and relative cell function curves.

Alice Krebs1,2, Johanna Nyffeler1,3, Jörg Rahnenführer4, Marcel Leist1,2,5.   

Abstract

Many types of assays in cell biology, pharmacology and toxicology generate data in which a parameter is measured in a reference system (negative control) and then also under conditions of increasing stress or drug exposure. To make such data easily comparable, they are normalized, i.e., the initial value of the system (e.g., viability or transport function) is set to 100%, and all data are indicated relative to this value. Then, curves are fitted through the data points and summary data of the system behavior are determined. For this, a benchmark response (BMR) is given (e.g., a curve drop by 15 or 50%), and the corresponding benchmark concentration (BMC15 or BMC50) is determined. Especially for low BMRs, this procedure is not very robust and often results in incorrect summary data. It is often neglected that a second normalization (re-normalization) is necessary to make the data suitable for curve fitting. It is also frequently overlooked that this requires knowledge of the system behavior at very low stress conditions. Here, good in vitro practice guidance for the re-normalization procedure is provided so that data of higher fidelity can be generated and presented.

Keywords:  BenchMarks series

Mesh:

Year:  2018        PMID: 29984806     DOI: 10.14573/1803231

Source DB:  PubMed          Journal:  ALTEX        ISSN: 1868-596X            Impact factor:   6.043


  3 in total

1.  The EU-ToxRisk method documentation, data processing and chemical testing pipeline for the regulatory use of new approach methods.

Authors:  Alice Krebs; Barbara M A van Vugt-Lussenburg; Tanja Waldmann; Wiebke Albrecht; Jan Boei; Bas Ter Braak; Maja Brajnik; Thomas Braunbeck; Tim Brecklinghaus; Francois Busquet; Andras Dinnyes; Joh Dokler; Xenia Dolde; Thomas E Exner; Ciarán Fisher; David Fluri; Anna Forsby; Jan G Hengstler; Anna-Katharina Holzer; Zofia Janstova; Paul Jennings; Jaffar Kisitu; Julianna Kobolak; Manoj Kumar; Alice Limonciel; Jessica Lundqvist; Balázs Mihalik; Wolfgang Moritz; Giorgia Pallocca; Andrea Paola Cediel Ulloa; Manuel Pastor; Costanza Rovida; Ugis Sarkans; Johannes P Schimming; Bela Z Schmidt; Regina Stöber; Tobias Strassfeld; Bob van de Water; Anja Wilmes; Bart van der Burg; Catherine M Verfaillie; Rebecca von Hellfeld; Harry Vrieling; Nanette G Vrijenhoek; Marcel Leist
Journal:  Arch Toxicol       Date:  2020-07-06       Impact factor: 5.153

2.  In Vitro Research Reproducibility: Keeping Up High Standards.

Authors:  Cordula Hirsch; Stefan Schildknecht
Journal:  Front Pharmacol       Date:  2019-12-10       Impact factor: 5.810

3.  Setting the stage for next-generation risk assessment with non-animal approaches: the EU-ToxRisk project experience.

Authors:  M J Moné; G Pallocca; S E Escher; T Exner; M Herzler; S Hougaard Bennekou; H Kamp; E D Kroese; Marcel Leist; T Steger-Hartmann; B van de Water
Journal:  Arch Toxicol       Date:  2020-09-04       Impact factor: 5.153

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.